Loading cancer entity…
Loading cancer entity…
Clinical trials
673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | terminated | Phase 1 / Phase 2 | 21 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 |
| clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | terminated | Phase 2 / Phase 3 | 52 | Y-mAbs TherapeuticsINDUSTRY | 4 | Feb 13, 2024 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT02641782 | NB2013-HR German (GPOH) / Dutch (DCOG) Trial(NB2013-HR) | terminated | Phase 2 | 3 | University of CologneOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT00202930 | Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma | terminated | Phase 2 | 4 | Jean M. Tersak, M.D.OTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT00698009 | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma | terminated | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00539500 | Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | terminated | Phase 2 / Phase 3 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 26, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | terminated | Phase 1 / Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00617890 | A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) | terminated | Phase 2 | 219 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 23, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00003515 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors | terminated | Phase 2 | 1 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00003513 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT00808899 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | terminated | Phase 2 | 4 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01440283 | A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma | terminated | Phase 2 | 14 | St. Jude Children's Research HospitalOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00969722 | A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | terminated | Phase 2 | 1 | United TherapeuticsINDUSTRY | 1 | Mar 8, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 16, 2025source: clinicaltrials